Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 5/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 5/20 | 0.34 |
| ▸ | TP53 | P04637 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 4/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7075194 | 0.93 | ACSS2 (0.36) | ACSS2OPRM1OPRD1OPRK1MAPT | |
| SCHEMBL7073469 | 0.92 | ACSS2 (0.36) | ACSS2OPRM1OPRD1OPRK1MAPT | |
| SCHEMBL7071950 | 0.92 | MTNR1A (0.35) | ACSS2OPRM1OPRD1OPRK1MAPT | |
| SCHEMBL7073159 | 0.80 | TP53 (0.36) | ACSS2MAPTTP53 | |
| SCHEMBL7072446 | 0.79 | LMNA (0.41) | ACSS2TP53LMNAPOLBALDH1A1 | |
| SCHEMBL7073312 | 0.78 | TRPV1 (0.37) | ACSS2OPRM1OPRD1OPRK1MAPT | |
| SCHEMBL7072215 | 0.78 | OPRM1 (0.36) | ACSS2OPRM1OPRD1OPRK1MAPT | |
| SCHEMBL7126377 | 0.78 | NR1H4 (0.33) | MAPTLMNAPOLBALDH1A1 | |
| SCHEMBL7126368 | 0.78 | NR1H4 (0.32) | MAPTPOLB | |
| SCHEMBL7067718 | 0.77 | TRPV1 (0.40) | ACSS2MAPTTRPV1POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | AXYS PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | CMA1, TPSG1, TPSD1 | ACSS2 746/4885OPRM1 1617/4885OPRD1 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.